title: A new rat model of otitis media caused by Streptococcus pneumoniae: conditions and application in immunization protocols.
abstract: Streptococcus pneumoniae (pneumococcus [Pn]) can be cultured from up to 50% of acute otitis media (AOM) effusions, and these bacteria are the most common cause of AOM-related complications. With the recent advent of antibiotic-resistant Pn strains, treatment of Pn infections may meet with serious difficulties. Prevention through vaccination, notably for the four most common occurring Pn serotypes in humans (i.e., Pn 6B, Pn 14, Pn 19F, and Pn 23F), is a helpful alternative. Testing of vaccine efficacy should occur in an appropriate animal AOM model, which is presented here. The four involved Pn serotypes are not pathogenic to the rat, which was chosen as the experimental animal for practical reasons. To induce a natural infection (i.e., ascending through the eustachian tube), the mucociliary clearance of the eustachian tube was impaired by infusing histamine into the tympanic cavity on 2 consecutive days before intranasal inoculation of the bacteria. With this simple protocol, high and reproducible infection rates, as determined with bacterial cultures, of Pn-induced AOM (approximately 70%) with the two major Pn serotypes 14 and 19F (Pn 14 and Pn 19F) were obtained, whereas lower infection rates (25 to 50%) with Pn 6B and Pn 23F were obtained. In this model, intranasal priming with pneumococci, as well as subcutaneous vaccination with Pn 14 tetanus toxoid-conjugated polysaccharide, induced a protective effect against the induction of otitis media with these bacteria. This shows that immunity to Pn 14 AOM can be induced by both mucosal and systemic presentations of antigen. In conclusion, we have developed an animal model for Pn-induced AOM, which is suitable for the evaluation of the protecting effect of immunization.
authors.affiliation: Laboratory of Pathology, National Institute of Public Health and the Environment, Bilthoven, The Netherlands. L.van.der.ven@rivm.nl
authors.forename: L T
authors.initials: LT
authors.lastname: van der Ven
authors.forename: G P
authors.initials: GP
authors.lastname: van den Dobbelsteen
authors.forename: B
authors.initials: B
authors.lastname: Nagarajah
authors.forename: H
authors.initials: H
authors.lastname: van Dijken
authors.forename: P M
authors.initials: PM
authors.lastname: Dortant
authors.forename: J G
authors.initials: JG
authors.lastname: Vos
authors.forename: P J
authors.initials: PJ
authors.lastname: Roholl
mesh_terms: D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D006632:Histamine / Q000494:pharmacology; D010033:Otitis Media / Q000209:etiology / Q000517:prevention & control*; D011008:Pneumococcal Infections / Q000517:prevention & control*; D051381:Rats; D013745:Tetanus Toxoid / Q000276:immunology; D014611:Vaccination
chemical_list: D001428:Bacterial Vaccines; D013745:Tetanus Toxoid; D006632:Histamine